SCHEMBL5368790

SCHEMBL5368790

Cc1cc(C)c(C=C2C(=O)Nc3ccc(C(=O)OCc4ccccc4)cc32)[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 1/20 0.66
PAK4 O96013 1/20 0.61
KDR P35968 6/20 0.61
PDPK1 O15530 2/20 0.61
RET P07949 10/20 0.58
FLT3 P36888 4/20 0.58
ALK Q9UM73 4/20 0.58
PDGFRB P09619 3/20 0.58
PDGFRA P16234 3/20 0.58
FLT1 P17948 3/20 0.58
CSF1R P07333 2/20 0.58
FGFR1 P11362 2/20 0.58
SRC P12931 2/20 0.58
FGFR3 P22607 2/20 0.58
MAPK1 P28482 2/20 0.58
FLT4 P35916 2/20 0.58
ABL1 P00519 2/20 0.58
NTRK1 P04629 2/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369648 0.88 TLK2 (0.74) TLK2PAK4KDRPDPK1RET
SCHEMBL5362637 0.84 TLK2 (0.77) TLK2PAK4KDRPDPK1RET
SCHEMBL5368286 0.83 PAK4 (0.69) TLK2PAK4KDRPDPK1RET
SCHEMBL5367680 0.83 PDGFRB (0.70) TLK2KDRRETFLT3ALK
SCHEMBL14519103 0.82 TLK2 (0.82) TLK2PAK4KDRPDPK1RET
SCHEMBL16568378 0.82 TLK2 (0.82) TLK2PAK4KDRPDPK1RET
SCHEMBL5364206 0.82 JAK3 (0.47) TLK2PAK4KDRPDPK1MEN1
SCHEMBL5469616 0.81 KDR (0.81) KDRPDPK1RETFLT3ALK
SCHEMBL5469611 0.81 KDR (0.81) KDRPDPK1RETFLT3ALK
SCHEMBL5364938 0.79 PDPK1 (0.70) TLK2PAK4KDRPDPK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK TLK2 48/4885PAK4 682/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.